Whether they recognise it or not, the entire pharma industry is involved in the business of health equity and championing it is critically important, Reshema Kemps-Polanco, chief commercial officer of Novartis, told attendees at Reuters Pharma USA 2024.
(CTN News) - The US Food and Drug Administration authorised Xolair, a medicine that reduces the intensity of allergy reactions in those who are allergic to
Xolair, which is developed and co-promoted by Genentech and Novartis in the US, was originally approved in 2003 for the treatment of moderate to severe persistent allergic asthma in certain patients.
FDA approves medication used to treat asthma for use in people with multiple food allergies ktvz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ktvz.com Daily Mail and Mail on Sunday newspapers.
Xolair, which is developed and co-promoted by Genentech and Novartis in the US, was originally approved in 2003 for the treatment of moderate to severe persistent allergic asthma in certain